Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Sci ; 106(11): 3402-3409, 2017 11.
Article in English | MEDLINE | ID: mdl-28634121

ABSTRACT

Tobramycin inhalation solution given as a twice daily inhalation of nebulized aerosols of 300 mg is approved for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients over 6 years of age. To investigate tobramycin pharmacokinetics (PK) after inhalation of tobramycin in pediatric cystic fibrosis patients below 7 years, a population PK approach was used to evaluate tobramycin PK data in patients 6 months to 44 years of age from 4 clinical studies. The final model used a 2-compartmental, first-order absorption model with effect of body mass index on the apparent central volume of distribution. Relative bioavailability in patients between 6 months and 7 years increased with age by a linear relationship, and was modeled as a ratio to that of patients over 7 years. Simulation showed that steady-state concentrations of tobramycin are lower in pediatric patients 6 months to 6 years than those in patients over 6 years. However, systemic exposure is not predictive of clinical efficacy due to direct dosing at the infection site. P aeruginosa eradication rate and safety profile in patients less than 7 years of age were similar to patients older than 6 years; therefore, no dose adjustment is warranted in the younger pediatric patients.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Cystic Fibrosis/complications , Pseudomonas Infections/complications , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Tobramycin/pharmacokinetics , Administration, Inhalation , Adolescent , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Biological Availability , Child , Child, Preschool , Computer Simulation , Cystic Fibrosis/drug therapy , Female , Humans , Infant , Male , Models, Biological , Tobramycin/administration & dosage , Tobramycin/blood , Treatment Outcome , Young Adult
3.
Int Arch Allergy Immunol ; 160(1): 102-10, 2013.
Article in English | MEDLINE | ID: mdl-22948442

ABSTRACT

BACKGROUND: Omalizumab has been shown to suppress responses to inhaled allergens in allergic asthma patients with pretreatment immunoglobulin E (IgE) ≤700 IU/ml. To extend current dosing tables, we evaluated the potential of high omalizumab doses to block allergen-induced bronchoconstriction in patients with higher IgE levels. METHODS: Asthmatic adults (18-65 years; body weight 40-150 kg) were divided into groups according to screening IgE (group 1: 30-300 IU/ml; group 2: 700-2,000 IU/ml) and randomized 2:1 to omalizumab/placebo every 2 or 4 weeks for 12-14 weeks. Allergen bronchoprovocation (ABP) testing was performed before treatment and at weeks 8 and 16. The primary efficacy endpoint, the early-phase allergic response (EAR), was defined as the maximum percentage drop in forced expiratory volume in 1 s during the first 30 min after ABP. Serum free IgE was determined as a pharmacodynamic endpoint, and the exhaled fractional concentration of nitric oxide (FE(NO)) was an exploratory endpoint. RESULTS: Fifty patients were included in the study. Omalizumab improved EAR; at week 8, EAR was 23.1% for placebo, 9.3% in group 1 (p = 0.018 versus placebo) and 5.6% in group 2 (p < 0.001). At week 16, EAR was 20%, 11.8% (p = 0.087) and 5.1% (p < 0.001), respectively. Free IgE decreased in groups 1 and 2 and remained <50 ng/ml in all patients during weeks 6-16. Omalizumab completely suppressed FE(NO) increases after ABP in both groups. CONCLUSIONS: Omalizumab blocked early asthmatic responses over a broad range of IgE/body weight combinations. Extending the dosing tables enables omalizumab to benefit a wider range of patients.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Asthma/drug therapy , Adolescent , Adult , Aged , Anti-Asthmatic Agents/administration & dosage , Antibodies, Anti-Idiotypic/administration & dosage , Antibodies, Monoclonal, Humanized/administration & dosage , Asthma/physiopathology , Asthma/prevention & control , Bronchial Provocation Tests , Bronchoconstriction/drug effects , Double-Blind Method , Female , Forced Expiratory Volume/drug effects , Humans , Immunoglobulin E/blood , Immunoglobulin E/immunology , Male , Middle Aged , Omalizumab , Treatment Outcome , Young Adult
4.
Pharm Stat ; 10(1): 45-9, 2011.
Article in English | MEDLINE | ID: mdl-20143341

ABSTRACT

For first-time-in-human studies with small molecules alternating cross-over designs are often employed and at study end are analyzed using linear models. We discuss the impact of including a period effect in the model on the precision with which dose level contrasts can be estimated and quantify the bias of least squares estimators if a period effect is inherent in the data that is not accounted for in the model. We also propose two alternative designs that allow a more precise estimation of dose level contrasts compared with the standard design when period effects are included in the model.


Subject(s)
Clinical Trials, Phase I as Topic/statistics & numerical data , Cross-Over Studies , Demography/statistics & numerical data , Dose-Response Relationship, Drug , Humans , Research Design
5.
Dermatology ; 221(4): 342-51, 2010.
Article in English | MEDLINE | ID: mdl-21099191

ABSTRACT

AIM: To evaluate the systemic exposure of pimecrolimus cream 1% applied under occlusion in atopic dermatitis (AD) patients. METHODS: A noncomparative, open-label study conducted in 3 groups of moderate to severe AD patients: A (adults, n = 9), B (adolescents, n = 4) and C (children, n = 6). Pimecrolimus cream 1% was applied twice daily for 8.5 days with overnight occlusion in patients with investigator's global assessment scores of ≥3 and AD involving at least 30% of their body surface area. Pimecrolimus blood concentrations were analyzed. RESULTS: The highest pimecrolimus blood concentrations observed in adults, adolescents and children were 1.84, 0.55 and 1.29 ng/ml, respectively. Pimecrolimus blood concentrations and affected body surface area showed no apparent correlation. CONCLUSION: No measurable differences were found in pimecrolimus blood concentrations, efficacy and safety profile when pimecrolimus cream 1% was applied under occlusion versus application without occlusion. These findings reflect the high lipophilic properties of pimecrolimus.


Subject(s)
Dermatitis, Atopic/drug therapy , Immunosuppressive Agents/pharmacokinetics , Skin Absorption , Tacrolimus/analogs & derivatives , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Male , Severity of Illness Index , Tacrolimus/administration & dosage , Tacrolimus/blood , Tacrolimus/pharmacokinetics , Treatment Outcome , Young Adult
6.
Biom J ; 51(1): 146-58, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19219906

ABSTRACT

Procedures for deconvolution of pharmacokinetic data are routinely used in the pharmaceutical industry to determine drug release and absorption which is essential in designing optimized drug formulations. Although these procedures are described extensively in the pharmacokinetic literature, they have been studied less from a statistical point of view and variance estimation has not been addressed. We discuss the statistical properties of a numerical procedure for deconvolution. Based on a point-area deconvolution method we define an estimator for the function that describes the time course of drug release from a drug formulation. Asymptotic distributions are derived and several methods of variance and interval estimation are compared.


Subject(s)
Drug Therapy, Computer-Assisted/methods , Models, Biological , Models, Statistical , Pharmaceutical Preparations/administration & dosage , Pharmaceutical Preparations/metabolism , Pharmacokinetics , Computer Simulation , Data Interpretation, Statistical , Humans , Metabolic Clearance Rate
7.
J Clin Pharmacol ; 45(8): 947-53, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16027406

ABSTRACT

Published data indicate that coadministration of multiple doses of the fibrate drug, gemfibrozil, led to a 202% increase in pravastatin systemic exposure (area under the plasma concentration-time curve, AUC). To evaluate the effects of another fibrate drug, fenofibrate, on the pharmacokinetics of pravastatin, 24 healthy subjects took pravastatin (40 mg once daily) on study days 1 to 15 and fenofibrate (160 mg once daily) on study days 6 to 15. Blood samples were collected for 24 hours after dosing on days 5, 6, and 15. Plasma concentrations of pravastatin and its active metabolite, 3alpha-hydroxy-iso-pravastatin, were measured, and pharmacokinetics was assessed. Safety assessments were based on adverse events, physical examinations, electrocardiogram results, vital signs, and clinical laboratory testing. Safety results were unremarkable. Coadministration of fenofibrate had modest effects on pravastatin and 3alpha-hydroxy-iso-pravastatin systemic exposures (AUC). Increases in pravastatin systemic exposures (19%-28%, on average) and 3alpha-hydroxy-iso-pravastatin systemic exposures (24%-39%, on average) were observed upon coadministration, but individual changes were variable. Pravastatin and 3alpha-hydroxy-iso-pravastatin systemic exposures were not statistically significantly different following the 1st and 10th doses of fenofibrate.


Subject(s)
Anticholesteremic Agents/pharmacokinetics , Fenofibrate/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Hypolipidemic Agents/pharmacology , Pravastatin/pharmacokinetics , Adult , Anticholesteremic Agents/administration & dosage , Anticholesteremic Agents/blood , Area Under Curve , Drug Interactions , Female , Fenofibrate/administration & dosage , Half-Life , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood , Hypolipidemic Agents/administration & dosage , Isomerism , Male , Metabolic Clearance Rate , Middle Aged , Pravastatin/administration & dosage , Pravastatin/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...